Figure 3

Validation of the cell line signature for tamoxifen in a meta-set of 439 breast cancer patients treated with tamoxifen. Kaplan-Meier plot of relapse free survival for patients predicted to be sensitive versus resistant to tamoxifen according to the 174-gene cell line-based predictor.